Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004618299 | SCV005112870 | uncertain significance | not specified | 2024-04-15 | criteria provided, single submitter | clinical testing | The c.213T>G (p.H71Q) alteration is located in exon 2 (coding exon 1) of the FBXO39 gene. This alteration results from a T to G substitution at nucleotide position 213, causing the histidine (H) at amino acid position 71 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |